
XMReality - Record sales pipeline and stellar cost control

Redeye states that the company has demonstrated excellent cost control during the first quarter of 2023, as evidenced by the noteworthy margin improvement. However, sales showed a modest increase, while ARR grew flat. In response to the report, we have made minor adjustments to our estimates while maintaining our fair value range and base case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

XMReality - Record sales pipeline and stellar cost control